Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with standard-of-care FLOT chemotherapy demonstrated a statistically ...

Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca’s (AZN) WAINZUA eplontersen has been approved in the European Union EU for ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal. When added to a ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as a perioperative treatment for patients with resectable ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as a "growing global hub" for clinical trials. The C$820 million ...

Add articles to your saved list and come back to them any time. It was the feelgood story of the Academy Awards this week – the little-known animated film Flow winning the first Oscar for the ...

Other 2025 highlights include "The Bad Guys 2," "Dog Man," "The SpongeBob Movie: Search for Square Pants," "The Magnificent Life of Marcel Pagnol," "The Twits," and possibly "Wildwood." It’s ...

After hours: March 11 at 7:57:42 PM EDT Loading Chart for AZN ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.